Seroatlas · Human Serome Atlas

AMPD3

AMP deaminase 3

Also known as: AMPD3_HUMAN

Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene

Protein identityUniProt · HPA

UniProt accession
Q01432
Gene
AMPD3
Ensembl
ENSG00000133805
Chromosome
11
Canonical length
767 aa
Protein class
Disease related genes, Enzymes, Human disease related genes, Metabolic proteins, Plasma proteins, Potential drug targets, Predicted intracellular proteins
Subcellular location
Nuclear membrane,Nucleoli
Quaternary structure
Homotetramer

OverviewNCBI Gene

This gene encodes a member of the AMP deaminase gene family. The encoded protein is a highly regulated enzyme that catalyzes the hydrolytic deamination of adenosine monophosphate to inosine monophosphate, a branch point in the adenylate catabolic pathway. This gene encodes the erythrocyte (E) isoforms, whereas other family members encode isoforms that predominate in muscle (M) and liver (L) cells. Mutations in this gene lead to the clinically asymptomatic, autosomal recessive condition erythrocyte AMP deaminase deficiency. Alternatively spliced transcript variants encoding different isoforms of this gene have been described. [provided by RefSeq, Jul 2008]

Canonical amino-acid sequenceUniProt

767 residues, UniProt reviewed canonical sequence.

>Q01432|AMPD3
     1  MPRQFPKLNI SEVDEQVRLL AEKVFAKVLR EEDSKDALSL FTVPEDCPIG QKEAKERELQ
    61  KELAEQKSVE TAKRKKSFKM IRSQSLSLQM PPQQDWKGPP AASPAMSPTT PVVTGATSLP
   121  TPAPYAMPEF QRVTISGDYC AGITLEDYEQ AAKSLAKALM IREKYARLAY HRFPRITSQY
   181  LGHPRADTAP PEEGLPDFHP PPLPQEDPYC LDDAPPNLDY LVHMQGGILF VYDNKKMLEH
   241  QEPHSLPYPD LETYTVDMSH ILALITDGPT KTYCHRRLNF LESKFSLHEM LNEMSEFKEL
   301  KSNPHRDFYN VRKVDTHIHA AACMNQKHLL RFIKHTYQTE PDRTVAEKRG RKITLRQVFD
   361  GLHMDPYDLT VDSLDVHAGR QTFHRFDKFN SKYNPVGASE LRDLYLKTEN YLGGEYFARM
   421  VKEVARELEE SKYQYSEPRL SIYGRSPEEW PNLAYWFIQH KVYSPNMRWI IQVPRIYDIF
   481  RSKKLLPNFG KMLENIFLPL FKATINPQDH RELHLFLKYV TGFDSVDDES KHSDHMFSDK
   541  SPNPDVWTSE QNPPYSYYLY YMYANIMVLN NLRRERGLST FLFRPHCGEA GSITHLVSAF
   601  LTADNISHGL LLKKSPVLQY LYYLAQIPIA MSPLSNNSLF LEYSKNPLRE FLHKGLHVSL
   661  STDDPMQFHY TKEALMEEYA IAAQVWKLST CDLCEIARNS VLQSGLSHQE KQKFLGQNYY
   721  KEGPEGNDIR KTNVAQIRMA FRYETLCNEL SFLSDAMKSE EITALTN

LocalizationUniProt · AlphaFold · HPA

Whether an antibody against AMPD3 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.

Antibody reachability
Secreted
Secreted
Yes
Transmembrane segments
0
Mean surface accessibility (rSASA)
0.25
Highest tissue expression
61 nTPM

Expression across tissuesHPA

Tissue

  • skeletal muscle: 61 nTPM
  • bone marrow: 57 nTPM
  • parathyroid gland: 22 nTPM
  • appendix: 19 nTPM
  • tonsil: 18 nTPM
  • adrenal gland: 17 nTPM

Single-cell type

  • neutrophil progenitors: 229 nCPM
  • gonadotrophs: 203 nCPM
  • neutrophils: 187 nCPM
  • epididymal clear cells: 182 nCPM
  • thymic myoid cells: 162 nCPM
  • thyrotrophs: 151 nCPM

Immune cell

  • eosinophil: 19 nTPM
  • basophil: 9.5 nTPM
  • neutrophil: 8.4 nTPM
  • memory B-cell: 7.5 nTPM
  • classical monocyte: 6.2 nTPM
  • MAIT T-cell: 5.3 nTPM

Brain region

  • white matter: 60 nTPM
  • basal ganglia: 47 nTPM
  • medulla oblongata: 45 nTPM
  • thalamus: 45 nTPM
  • pons: 44 nTPM
  • midbrain: 43 nTPM

DiseaseUniProt · ClinVar · IEDB · PubMed

Four sources answering four different questions about AMPD3.

Disease | AllUniProt

Conditions AMPD3 is implicated in, by any mechanism.

Disease | GeneticClinVar

4 pathogenic / likely-pathogenic of 234 ClinVar records.

Conditions with pathogenic or likely-pathogenic variants.

Genetic constraint and essentialitygnomAD · DepMap

Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.

gnomAD LOEUF (loss-of-function intolerance)
0.91
gnomAD pLI
0
gnomAD missense Z
0.67
DepMap mean gene effect
-0.01
DepMap dependency class
selective

Cancer expressionTCGA

Across TCGA tumor cohorts, this protein is over-expressed in roughly 4% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).

OntologyGO

Biological processes

Molecular functions

Cellular components

Protein domainsUniProt · Pfam · InterPro

KeywordsUniProt

Antibody and autoantibody relevanceSeroatlas analysis

Seroatlas reads AMPD3 as an antibody target. Whether an autoantibody or antibody against AMPD3 could matter depends on whether native AMPD3 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.

AMPD3 is annotated as secreted, so native AMPD3 circulates and is directly accessible to antibodies. Secreted and cell-surface proteins are the autoantibody targets most likely to act like drugs, blocking or depleting the native protein.

Annotation status

The present source text does not explicitly label AMPD3 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.

Canonical record: https://seroatlas.com/gene/AMPD3. Study-independent annotations aggregated from UniProt, Human Protein Atlas, PubMed, IEDB, Pfam, InterPro, Gene Ontology, AlphaFold, gnomAD, DepMap, ClinVar, TCGA. Catalog release seroatlas-reviewed-human-uniprot-20260313.

Seroatlas is the reference for exploring autoantibody and antibody serology at the human-protein level: the autoreactome and human serome, multiplex serology (HuProt, HuScan, VirScan, PhIP-Seq).

Loading the interactive Seroatlas protein explorer...